Kinetics of Nirogacestat-Mediated Increases in B-cell Maturation Antigen on Plasma Cells Inform Therapeutic Combinations in Multiple Myeloma

Cancer Res Commun. 2024 Dec 1;4(12):3114-3123. doi: 10.1158/2767-9764.CRC-24-0075.

Abstract

GSIs can enhance multiple myeloma therapies targeting BCMA by increasing mbBCMA on plasma cells. In response to the GSI nirogacestat, mbBCMA rapidly and robustly increased in vitro and in vivo. Elucidating nirogacestat's effects on BCMA kinetics will guide potential multiple myeloma dosing strategies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • B-Cell Maturation Antigen* / immunology
  • Cell Line, Tumor
  • Humans
  • Kinetics
  • Mice
  • Multiple Myeloma* / drug therapy
  • Multiple Myeloma* / immunology
  • Multiple Myeloma* / pathology
  • Multiple Myeloma* / therapy
  • Plasma Cells* / drug effects
  • Plasma Cells* / immunology
  • Xenograft Model Antitumor Assays

Substances

  • B-Cell Maturation Antigen